FDA warns 350 practices against unapproved versions of Botox

12/28/2012 | Medical News Today

The FDA warned more than 350 medical practices regarding unapproved versions of wrinkle fighter Botox as well as other drugs from Canada Drugs and its subsidiaries. The products could be unsafe, ineffective, counterfeit and contaminated, the FDA said. The FDA asked the practices to stop using the treatments in patients.

View Full Article in:

Medical News Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC